Search clinical trials for: DIMS0150

Total 3 results

InDex Pharmaceuticals

Terminated

The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis (CONCLUDE)

Ulcerative Colitis

Korea, Republic of, United Kingdom, United States, Mexico, Belgium, Netherlands, Denmark, Poland, Israel, Germany, France, Australia, Austria, Canada, Lithuania, Croatia, Italy, Romania, Turkey, Portugal, Slovakia, Hungary, Norway, Bosnia... and more
InDex Pharmaceuticals

Completed

The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis (CONDUCT)

Ulcerative Colitis

Hungary, Czechia, France, Germany, Poland, Russian Federation, Serbia, Spain, Sweden, Ukraine
InDex Pharmaceuticals

Completed

The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis Patients (COLLECT)

Colitis, Ulcerative

Czechia, France, Germany, Hungary, Italy, Poland, United Kingdom

3

Subscribe